Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety

Murphy, EL

doi:10.1016/j.tracli.2015.12.001

Cited by 72 publications

(64 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although HTLV-1 was discovered in 1979, there is no recommendation for systematic screening worldwide. In particular, HTLV-1 prevalence is still poorly understood in several areas of East and North Africa and most parts of Asia, due mainly to a lack of solid data (Murphy, 2016). Furthermore, HTLV-1 and simian T-lymphotropic virus type 1 (STLV-1) can be considered as a single virus infecting and inducing diseases in two different species (Enose-Akahata et al, 2016).…”

Section: Research Priorities and Open Questionsmentioning

confidence: 99%

“…This article presents the consensus views of taskforce members regarding unsolved or controversial issues that hamper further understanding of HTLV-1 and the development of new approaches for diagnosis, prevention and therapy. For additional information on the molecular mechanisms of pathogenesis, immunological aspects, epidemiology and currently available therapies for HTLV-1 infection, readers are referred to a number of excellent review articles (Bangham et al, 2015;Matsuoka and Jeang, 2007;Pique and Jones, 2012;Murphy, 2016;Gessain and Cassar, 2012;Kato and Akashi, 2015).…”

Section: Introduction: the Global Burden Of Htlv-1 Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Reducing the global burden of HTLV-1 infection: An agenda for research and action

et al. 2017

View full text Add to dashboard Cite

a b s t r a c tEven though an estimated 10e20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In * Corresponding author. Molecular and Cellular Epigenetics, Interdisciplinary Cluster for Applied Genoproteomics (GIGA) of University of Liege (ULg), B34, 1 Avenue de l'Hôpital, 4000, Sart-Tilman, Liege, Belgium.E-mail address: luc.willems@ulg.ac.be (L. Willems). Contents lists available at ScienceDirect Antiviral Researchj o u rn a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / a n t iv i r a l the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

show abstract

Section: Research Priorities and Open Questionsmentioning

confidence: 99%

Section: Introduction: the Global Burden Of Htlv-1 Infectionmentioning

confidence: 99%

Reducing the global burden of HTLV-1 infection: An agenda for research and action

et al. 2017

View full text Add to dashboard Cite

show abstract

“…This has been achieved by a combination of community education, non-remunerated voluntary blood donations, pre-donation donor questionnaires designed to elicit risk behaviors, universal donor screening, pathogen inactivation procedures incorporated into the production of plasma-derived products and the availability of pathogen reduction technologies for fresh blood components [2,[4][5][6][7]. Additionally, most countries perform serological screening for Treponema pallidum (syphilis) [8], while a number also screen for antibodies to human T-cell lymphotropic virus types 1 and 2 (anti-HTLV-1/2) [9,10] and bacterial contamination of platelet components [11].…”

mentioning

confidence: 99%

Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk

Kiely

Gambhir

Cheng

et al. 2017

Transfusion Medicine Reviews

View full text Add to dashboard Cite

While the transfusion-transmission (TT) risk associated with the major transfusion-relevant viruses such as HIV is now very low, during the last 20 years there has been a growing awareness of the threat to blood safety from emerging infectious diseases, a number of which are known to be, or are potentially, transfusion transmissible. Two published models for estimating the transfusion-transmission risk from EIDs, referred to as the Biggerstaff-Petersen model and the European Upfront Risk Assessment Tool (EUFRAT), respectively, have been applied to several EIDs in outbreak situations. We describe and compare the methodological principles of both models, highlighting their similarities and differences. We also discuss the appropriateness of comparing results from the two models. Quantitating the TT risk of EIDs can inform decisions about risk mitigation strategies and their cost-effectiveness. Finally, we present a qualitative risk assessment for Zika virus (ZIKV), an EID agent that has caused several outbreaks since 2007. In the latest and largest ever outbreak, several probable cases of transfusion-transmission ZIKV have been reported, indicating that it is transfusion-transmissible and therefore a risk to blood safety. We discuss why quantitative modeling the TT risk of ZIKV is currently problematic.

show abstract

“…Therefore, laboratory screening assays for HTLV‐I/II in blood donors have been extensively implemented in developed countries and regions with high prevalence rate . Screening test for HTLV‐I/II has not been considered until a case of HTLV infection due to blood transfusion was identified for the first time in 2006 in Korea; anti‐HTLV‐I/II screening test using chemiluminescent microparticle immunoassay (CMIA) for blood donors was implemented in 2008.…”

Section: Introductionmentioning

confidence: 99%

“…7 Therefore, laboratory screening assays for HTLV-I/II in blood donors have been extensively implemented in developed countries and regions with high prevalence rate. 8 Screening test for HTLV-I/II has not been considered until a case of HTLV infection due to blood transfusion was identified for the first time in Conformité Européenne -marked Elecsys HTLV-I/II assay (Roche Diagnostics) has launched recently in Asian area. However, no clinical study using Korean specimens has been performed in terms of sensitivity and specificity so far.…”

mentioning

confidence: 99%

Evaluation of Elecsys HTLV‐I/II assay in comparison with ARCHITECT rHTLV‐I/II assay with Korean samples

Yun

Kim

Sohn³

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundThe seroprevalence rate of human T‐lymphotropic virus I and II (HTLV‐I/II) in Korean blood donors has been known as 0.004%, and HTLV‐I/II Ab screening test has been performed since 2008 in Korea. Korea Ministry of Food and Drug Safety (MFDS) approved two chemiluminescent microparticle immunoassays (CMIA) for testing HTLV‐I/II antibody, ABBOTT PRISM HTLV‐I/HTLV‐II and ARCHITECT rHTLV‐I/II. A multicenter performance evaluation study in Europe and Japan was carried out with the new electrochemiluminescence immunoassay (ECLIA) for HTLV‐I/II antibody detection, Elecsys HTLV‐I/II assay which launched in 2017, but not in Korea. We aimed to evaluate the clinical performance of Elecsys HTLV‐I/II assay in comparison with ARCHITECT rHTLV‐I/II for the detection of HTLV‐I/II antibody with Korean samples.MethodsFor sensitivity evaluation, 100 HTLV‐I/II‐positive Korean standards from Korean Red Cross and two HTLV‐II‐positive samples that were purchased from Seracure were used. For the specificity, 500 potential donor specimens from Korea University Hospital healthcare center were used. All the samples were simultaneously analyzed by the two HTLV‐I/II assays, Elecsys HTLV‐I/II assay and ARCHITECT rHTLV‐I/II assay.ResultsElecsys HTLV‐I/II assay and ARCHITECT rHTLV‐I/II assay showed a complete agrement. Elecsys HTLV‐I/II assay showed 100% sensitivity (95% CI: 96.38‐100.0) and specificity (95% CI: 99.26‐100.0).ConclusionsElecsys HTLV‐I/II assay is as reliable as ARCHITECT rTHLV‐I/II assay, and can be used as a screening test for HTLV‐I/II in Korea.

show abstract

Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety

Cited by 72 publications

References 41 publications

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Reducing the global burden of HTLV-1 infection: An agenda for research and action

Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk

Evaluation of Elecsys HTLV‐I/II assay in comparison with ARCHITECT rHTLV‐I/II assay with Korean samples

Contact Info

Product

Resources

About